SI1551868T1 - Faktor udeleĺ˝en pri metastazi in njegove uporabe - Google Patents

Faktor udeleĺ˝en pri metastazi in njegove uporabe

Info

Publication number
SI1551868T1
SI1551868T1 SI200331544T SI200331544T SI1551868T1 SI 1551868 T1 SI1551868 T1 SI 1551868T1 SI 200331544 T SI200331544 T SI 200331544T SI 200331544 T SI200331544 T SI 200331544T SI 1551868 T1 SI1551868 T1 SI 1551868T1
Authority
SI
Slovenia
Prior art keywords
metastasis
polypeptide
amino acid
extracellular matrix
sequence according
Prior art date
Application number
SI200331544T
Other languages
English (en)
Inventor
Anke Klippel-Giese
Jorg Kaufmann
Rolf Schwarzer
Original Assignee
Silence Therapeutics Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Silence Therapeutics Ag filed Critical Silence Therapeutics Ag
Publication of SI1551868T1 publication Critical patent/SI1551868T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI200331544T 2002-10-18 2003-10-20 Faktor udeleĺ˝en pri metastazi in njegove uporabe SI1551868T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02023384 2002-10-18
EP03769423A EP1551868B1 (en) 2002-10-18 2003-10-20 Factor involved in metastasis and uses thereof
PCT/EP2003/011604 WO2004035615A2 (en) 2002-10-18 2003-10-20 Factor involved in metastasis and uses thereof

Publications (1)

Publication Number Publication Date
SI1551868T1 true SI1551868T1 (sl) 2009-06-30

Family

ID=32103889

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200331544T SI1551868T1 (sl) 2002-10-18 2003-10-20 Faktor udeleĺ˝en pri metastazi in njegove uporabe

Country Status (19)

Country Link
US (2) US20060240022A1 (sl)
EP (2) EP2072619A1 (sl)
JP (2) JP4820092B2 (sl)
KR (1) KR101154130B1 (sl)
CN (1) CN100564524C (sl)
AT (1) ATE420102T1 (sl)
AU (2) AU2003278112A1 (sl)
BR (1) BR0315411A (sl)
CA (1) CA2501333A1 (sl)
CY (1) CY1110313T1 (sl)
DE (1) DE60325754D1 (sl)
DK (1) DK1551868T3 (sl)
ES (1) ES2319891T3 (sl)
IL (1) IL167801A (sl)
MX (1) MXPA05004134A (sl)
PT (1) PT1551868E (sl)
SI (1) SI1551868T1 (sl)
WO (1) WO2004035615A2 (sl)
ZA (1) ZA200502483B (sl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7405292B2 (en) * 2002-02-19 2008-07-29 The Children's Hospital Of Philadelphia Cellular genes regulated by HIV-1 infection and methods of use thereof
AU2003260370B2 (en) 2002-08-05 2008-05-22 Silence Therapeutics Gmbh Further novel forms of interfering RNA molecules
JP4820092B2 (ja) * 2002-10-18 2011-11-24 サイレンス・セラピューティクス・アーゲー 転移のための新規な因子及びその使用
AU2005277508B2 (en) 2004-08-16 2011-04-14 Quark Pharmaceuticals, Inc Therapeutic uses of inhibitors of RTP801
CN100357323C (zh) * 2006-01-05 2007-12-26 清华大学 一种细胞迁移相关蛋白及其编码基因与应用
US7825099B2 (en) 2006-01-20 2010-11-02 Quark Pharmaceuticals, Inc. Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes
NL2000439C2 (nl) * 2006-01-20 2009-03-16 Quark Biotech Therapeutische toepassingen van inhibitoren van RTP801.
FR2898908A1 (fr) 2006-03-24 2007-09-28 Agronomique Inst Nat Rech Procede de preparation de cellules aviaires differenciees et genes impliques dans le maintien de la pluripotence
US7723052B2 (en) 2006-05-11 2010-05-25 Quark Pharmaceuticals, Inc. Screening systems utilizing RTP801
WO2008106102A2 (en) 2007-02-26 2008-09-04 Quark Pharmaceuticals, Inc. Inhibitors of rtp801 and their use in disease treatment
EP2323695B1 (en) 2008-08-19 2018-12-05 Nektar Therapeutics Complexes of small-interfering nucleic acids
US8916693B2 (en) 2009-09-17 2014-12-23 Nektar Therapeutics Monoconjugated chitosans as delivery agents for small interfering nucleic acids
US9932578B2 (en) 2012-09-12 2018-04-03 Quark Pharmaceuticals, Inc. Double-stranded oligonucleotide molecules to P53 and methods of use thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR970002255B1 (ko) 1990-06-11 1997-02-26 넥스스타 파아마슈티컬드, 인크. 핵산 리간드
WO1998008856A2 (de) 1996-08-30 1998-03-05 Fuerste Jens Peter Spiegelselektion und spiegelevolution von nucleinsäuren
US6958239B2 (en) 1996-11-21 2005-10-25 Oligos Etc Inc. Three component chimeric antisense oligonucleotides
US5849902A (en) 1996-09-26 1998-12-15 Oligos Etc. Inc. Three component chimeric antisense oligonucleotides
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
JP2003525017A (ja) 1998-04-20 2003-08-26 リボザイム・ファーマシューティカルズ・インコーポレーテッド 遺伝子発現を調節しうる新規な化学組成を有する核酸分子
US5958773A (en) * 1998-12-17 1999-09-28 Isis Pharmaceuticals Inc. Antisense modulation of AKT-1 expression
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
CA2382748A1 (en) * 1999-06-11 2000-12-21 Human Genome Sciences, Inc. 50 human secreted proteins
US6133032A (en) * 1999-09-09 2000-10-17 Isis Pharmaceutical Inc. Antisense modulation of PI3 kinase p110 beta expression
WO2003070918A2 (en) 2002-02-20 2003-08-28 Ribozyme Pharmaceuticals, Incorporated Rna interference by modified short interfering nucleic acid
AU2001249622B2 (en) 2000-03-30 2007-06-07 Massachusetts Institute Of Technology RNA sequence-specific mediators of RNA interference
US6673545B2 (en) * 2000-07-28 2004-01-06 Incyte Corporation Prostate cancer markers
WO2002046465A2 (en) * 2000-12-08 2002-06-13 Oxford Biomedica (Uk) Limited Method for identification of genes involved in specific diseases
WO2003010205A1 (en) * 2001-07-26 2003-02-06 Duke University Medical Center Genes induced by hypoxia
JP2006514823A (ja) * 2002-08-20 2006-05-18 ミレニアム ファーマスーティカルズ インク 子宮頸癌の同定、評価、予防および治療を行うための組成物、キットおよび方法
JP4820092B2 (ja) * 2002-10-18 2011-11-24 サイレンス・セラピューティクス・アーゲー 転移のための新規な因子及びその使用
AU2005277508B2 (en) * 2004-08-16 2011-04-14 Quark Pharmaceuticals, Inc Therapeutic uses of inhibitors of RTP801

Also Published As

Publication number Publication date
BR0315411A (pt) 2005-08-16
ES2319891T3 (es) 2009-05-14
US20060240022A1 (en) 2006-10-26
JP2011125339A (ja) 2011-06-30
IL167801A (en) 2012-10-31
JP4820092B2 (ja) 2011-11-24
EP1551868B1 (en) 2009-01-07
CN100564524C (zh) 2009-12-02
KR20050056244A (ko) 2005-06-14
MXPA05004134A (es) 2005-10-05
CN1705746A (zh) 2005-12-07
WO2004035615A3 (en) 2004-06-03
CY1110313T1 (el) 2015-01-14
US20100285038A1 (en) 2010-11-11
ATE420102T1 (de) 2009-01-15
JP2006520183A (ja) 2006-09-07
AU2003278112A1 (en) 2004-05-04
WO2004035615A2 (en) 2004-04-29
KR101154130B1 (ko) 2012-06-12
DE60325754D1 (de) 2009-02-26
EP2072619A1 (en) 2009-06-24
EP1551868A2 (en) 2005-07-13
AU2010246370A1 (en) 2010-12-16
PT1551868E (pt) 2009-04-06
DK1551868T3 (da) 2009-04-20
ZA200502483B (en) 2005-11-30
CA2501333A1 (en) 2004-04-29

Similar Documents

Publication Publication Date Title
CY1110313T1 (el) Παραγοντας που εμπλεκεται στη μετασταση και οι χρησεις του
Joester et al. Evidence for combinatorial variability of tenascin-C isoforms and developmental regulation in the mouse central nervous system
Leyh et al. The DNA sequence of the sulfate activation locus from Escherichia coli K-12.
DK289688D0 (da) Ekspression af proapolipoprotein a-i.
HUP9900078A2 (hu) Eljárás O-acetilszerin, L-cisztein és L-cisztein-származékok előállítására
ATE317897T1 (de) System und methode zur herstellung von rekombinanten, glykosylierten protein in prokaryontischen wirtszellen
IS4884A (is) Ret bindill til örvunar vaxtar tauga og thvagfæra
DE69839768D1 (de) Rekombinante lactoferrin, verfahren zu ihrer herstellung mittels pflanzen und ihre verwendung
DK1003379T3 (da) Hidtil ukendt phytase
ES2089044T3 (es) Fragmento de dna que codifica un polipeptido que presenta actividad nitrilo hidratasa, un transformante que contiene el fragmento de dna y un proceso para la produccion de amidas utilizando el transformante.
Andersen et al. A new secreted insect protein belonging to the immunoglobulin superfamily binds insulin and related peptides and inhibits their activities
FI914420A0 (fi) Uusi, erittäin termostabiili -amylaasi
DK1472344T3 (da) Bakteriofaglysin
DE3853446D1 (de) Fibronectinbindungsprotein und dessen Herstellung.
WO1991016434A3 (en) Bacillus thuringiensis cryif and cryix genes and proteins toxic to lepidopteran insects
DE60235985D1 (de) Ntb-a, ein oberflächenmolekül impliziert in der aktivität natürlicher killerzellen (nk)
KR830003576A (ko) 인간의 프로인슐린선구물질과 프로인슐린 유전자를 분리, 정제하고 미생물에게 전달해서 복제하는 방법
BR9811853A (pt) Processos para aumentar o rendimento em plantas
DE602005019421D1 (de) Grosstechnisch geeigneter mikroorganismus
TR200000483T2 (tr) Yabancı protein ifadesinin arttırılması için yöntem.
ATE121456T1 (de) Klonierung und überexpression von glucose-6- phosphat-dehydrogenase aus leuconostoc dextranicus.
ATE220108T1 (de) Enzymatische umsetzung von proteinen unter verwendung immobilisierter dipeptidylaminopeptidase aus dictyostelium
Hilario et al. High-level production of functional muscle α-tropomyosin in Pichia pastoris
DK595187D0 (da) Minactivin og fremgangsmaade til fremstilling deraf
WO2000047723A3 (en) Human diacylglycerol kinase beta (hdagk beta) proteins and nucleotide sequences encoding the same